Cochrane · systematic review · CD011802
Stepping down the dose of inhaled corticosteroids for adults with asthma
Crossingham, I, Evans, DJW, Halcovitch, NR, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
12
No studies
2
Included studies
NR
No studies 2 · 14.3%Ungraded 0 · 0%Very low 4 · 28.6%Low 8 · 57.1%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
ICS dose reduction compared with no change in ICS dose (no concomitant LABA) for adults with asthma
Population: adults with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbation requiring OCS ICS dose reduction vs no change | OR 1.86 [0.16, 21.09] | 2 studies · 261 participants | Very low |
Asthma control assessed by: Asthma Symptom Scale from: 0 (no symptoms) to 5 (severe symptoms) ICS dose reduction vs no change | no estimate extracted | 1 study · 150 participants | Low |
All‐cause SAEs ICS dose reduction vs no change | OR 1.24 [0.25, 6.25] | 2 studies · 742 participants | Low |
Steroid‐related AEs ICS dose reduction vs no change | OR 0.76 [0.16, 3.54] | 2 studies · 261 participants | Very low |
Health‐related quality of life (change from baseline) assessed by: AQLQ ICS dose reduction vs no change | no estimate extracted | 1 study · 554 participants | Very low |
Lung function, FEV1 (L) assessed by: spirometry ICS dose reduction vs no change | no estimate extracted | 2 studies · 261 participants | Low |
Exacerbations requiring hospitalisation ‐ not reported ICS dose reduction vs no change | no estimate extracted | NR | No studies |
ICS dose reduction compared with no change in ICS dose (concomitant LABA) for adults with asthma
Population: adults with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbation requiring OCS ICS dose reduction vs no change | OR 1.31 [0.82, 2.08] | 2 studies · 569 participants | Low |
Asthma control (short asthma morbidity score) ICS dose reduction vs no change | no estimate extracted | 1 study · 242 participants | Low |
All‐cause SAEs ICS dose reduction vs no change | OR 0.6 [0.11, 3.33] | 2 studies · 569 participants | Low |
Steroid‐related AEs ‐ not reported ICS dose reduction vs no change | no estimate extracted | NR | No studies |
St. George's Respiratory Scale score (change from baseline) ICS dose reduction vs no change | no estimate extracted | 1 study · 229 participants | Low |
Exacerbation requiring hospitalisation ICS dose reduction vs no change | OR 4.06 [0.45, 36.86] | 2 studies · 569 participants | Low |
Lung function, reduction in FEV1 (% predicted, change from baseline) ICS dose reduction vs no change | no estimate extracted | 1 study · 14 participants | Very low |